Last Updated: September 28, 2026

Details for New Drug Application (NDA): 210655

✉ Email this page to a colleague

« Back to Dashboard

NDA 210655 describes PERSERIS KIT, which is a drug marketed by Indivior and is included in one NDA. There are ten patents protecting this drug. Additional details are available on the PERSERIS KIT profile page.

The generic ingredient in PERSERIS KIT is risperidone. There is one drug master file entry for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the risperidone profile page.

Summary for 210655

Tradename:	PERSERIS KIT
Applicant:	Indivior
Ingredient:	risperidone
Patents:	10

Medical Subject Heading (MeSH) Categories for 210655

Antipsychotic Agents
Dopamine Antagonists
Serotonin Antagonists

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS			Strength	90MG
Approval Date:	Jul 27, 2018	TE:		RLD:	Yes
Patent:	10,010,612	Patent Expiration:	Feb 13, 2028	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	10,058,554	Patent Expiration:	Sep 26, 2026	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	ADMINISTRATION OF RISPERIDONE
Patent:	10,376,590	Patent Expiration:	Feb 13, 2028	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	METHOD OF TREATING SCHIZOPHRENIA

Expired US Patents for NDA 210655

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Indivior	PERSERIS KIT	risperidone	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	210655-002	Jul 27, 2018	10,406,160	⤷ Start Trial
Indivior	PERSERIS KIT	risperidone	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	210655-002	Jul 27, 2018	10,058,554	⤷ Start Trial
Indivior	PERSERIS KIT	risperidone	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	210655-002	Jul 27, 2018	9,597,402	⤷ Start Trial
Indivior	PERSERIS KIT	risperidone	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	210655-001	Jul 27, 2018	10,058,554	⤷ Start Trial
Indivior	PERSERIS KIT	risperidone	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	210655-001	Jul 27, 2018	9,597,402	⤷ Start Trial
Indivior	PERSERIS KIT	risperidone	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	210655-001	Jul 27, 2018	10,406,160	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.